DiaMedica Therapeutics (DMAC) Free Cash Flow (2018 - 2026)

DiaMedica Therapeutics (DMAC) has reported Free Cash Flow for 9 consecutive years, with -$8.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Free Cash Flow fell 6.56% year-over-year to -$8.1 million; the trailing twelve-month figure through Jun 2026 stood at -$31.6 million (down 22.97% YoY), and the FY2025 full-year result was -$29.1 million, down 31.85% from the prior year.
• Free Cash Flow rose to -$8.1 million in Q2 2026 per DMAC's latest filing, from -$9.1 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$2.4 million in Q3 2022 and bottomed at -$9.1 million in Q1 2026.
• Historically, Free Cash Flow has averaged -$5.5 million across 5 years, with a median of -$5.1 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Free Cash Flow grew 21.13% in 2022, then plunged 101.2% in 2023.
• Over 5 years, Free Cash Flow stood at -$2.8 million in 2022, then sank by 36.35% to -$3.8 million in 2023, then plunged by 68.83% to -$6.4 million in 2024, then slipped by 21.19% to -$7.8 million in 2025, then decreased by 3.8% to -$8.1 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$8.1 million, -$9.1 million, and -$7.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.